DAW2020 / Brigham and Womens Hospital - LARVOL DELTA

Atomoxetine and DAW2022 on OSA Severity (clinicaltrials.gov) - P1/2 | N=18 | Recruiting | Sponsor: Brigham and Women's Hospital | Trial completion date: Jun 2023 ➔ Jun 2024 | Trial primary completion date: Jun 2023 ➔ Jun 2024

Trial completion date • Trial primary completion date • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Disorder

SedOSA: DAW2020 on OSA Endotypic Traits (clinicaltrials.gov) - P1/2 | N=20 | Enrolling by invitation | Sponsor: Brigham and Women's Hospital | Completed ➔ Enrolling by invitation | Trial completion date: Jun 2022 ➔ Jun 2024 | Trial primary completion date: May 2022 ➔ May 2024

Enrollment open • Trial completion date • Trial primary completion date • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Disorder

Atomoxetine and DAW2022 on OSA Severity (clinicaltrials.gov) - P1/2 | N=18 | Recruiting | Sponsor: Brigham and Women's Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Disorder

SedOSA: DAW2020 on OSA Endotypic Traits (clinicaltrials.gov) - P1/2 | N=20 | Completed | Sponsor: Brigham and Women's Hospital | Recruiting ➔ Completed

Trial completion • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Disorder

Atomoxetine and DAW2022 on OSA Severity (clinicaltrials.gov) - P1/2 | N=18 | Not yet recruiting | Sponsor: Brigham and Women's Hospital

New P1/2 trial • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Disorder